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Endometrial adenocarcinoma is the most frequently diagnosed cancer of the female genital tract in the western
world. Studies of complex diseases can be difficult to perform on human tumor samples due to the high genetic
heterogeneity in human. The use of rat models is preferable since rat has similarities in pathogenesis and
histopathological properties to that of human.
A genomic region including the highly conserved Phf5a gene associated to development of EAC has previously
been identified in an association study. PHF5A has been suggested to acts as a transcription factor or cofactor in
the up regulation of expression of Gja1 gene in the presence of estrogen. It has earlier been shown that the Phf5a
gene is down regulated in rat EAC derived cell lines by means of expression microarrays.
We analyzed the expression of Phf5a and Gja1 by qPCR, and potential relations between the two genes in EAC
tumors and non-malignant cell lines derived from the BDII rat model. In addition, the expression pattern of these
genes was compared in rat and human EAC tumor samples.
Changes in expression for Phf5a/PHF5A were found in tumors from both rat and human even though the observed
pattern was not completely consistent between the two species. By separating rat EAC cell lines according to the
genetic background, a significant lower expression of Phf5a in one of the two cross backgrounds was revealed, but
not for the other. In contrast to other studies, Phf5a/PHF5A regulation of Gja1/GJA1 was not revealed in this study.
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Endometrial carcinoma arises from the endometrium, the
inner lining of the uterus. Endometrial adenocarcinoma
(EAC), the predominant sub type, is the most frequently
diagnosed cancer of the female genital tract ranking
fourth among the invasive tumors that affect women in
the western world. Approximately 85% of the patients
with the diagnosis EAC are over 50 years of age [1]. As
most cancers, EAC is a complex disease and develop-
ment of the tumors is influenced by multiple genetic
alterations. As the endometrium is a hormone-dependent
tissue, tumors developed in this tissue, including
EACs, are mainly hormone-dependent [2]. It has been
suggested that excess administration of estrogen may
act as one of the main factors in predisposition to EAC
in women [3].* Correspondence: karin.klinga.levan@his.se
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distribution, and reproduction in any mediumStudies of complex diseases can be difficult to perform
on human tumor samples due to the high genetic het-
erogeneity in human. Therefore, in studies of complex
disease and as a complement to studies in human, model
organisms such as inbred rat strains are often used. The
use of rat models is preferable since rat has similarities
in pathogenesis and histopathological properties to those
of human [2,4]. In the EAC susceptible BDII rat strain,
more than 90% of the virgin females develop tumors
spontaneously during their lifetime. This tumor model
has been genetically well characterized, but there is still
much important genetic information that remains to be
fully understood in this model [5].
Associations between certain marker alleles and tumor
incidence in cross progenies, including the susceptible
BDII strain and non-susceptible strains, were identified
by means of genome-wide screening with microsatellites.
It was clear from the data on tumors developed in the
inter-strain crosses that the onset of tumors depends not
only on the presence of susceptibility alleles from theed Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
Table 1 Overview of the rat tumor material used in
this study
Tumor Background Pathology
NUT43 (BDIIxBN)xBDII EAC
NUT50 (BDIIxBN)xBDII EAC
NUT81 (BDIIxBN)xBDII EAC
NUT97 (BDIIxBN)xBDII EAC
NUT128 (BDIIxBN)xBDII EAC
NUT75 (BDIIxBN)xBDII NME
NUT110 (BDIIxBN)xBDII NME
NUT118 (BDIIxBN)xBDII NME
NUT122 (BDIIxBN)xBDII NME
NUT129 (BDIIxBN)xBDII NME
NUT7 (BDIIxSPRD)xBDII EAC
NUT12 (BDIIxSPRD)xBDII EAC
NUT41 (BDIIxSPRD)xBDII EAC
NUT42 (BDIIxSPRD)xBDII EAC
NUT47 (BDIIxSPRD)xBDII EAC
NUT84 (BDIIxSPRD)xBDII EAC
NUT48 (BDIIxSPRD)xBDII NME
NUT56 (BDIIxSPRD)xBDII NME
NUT58 (BDIIxSPRD)xBDII NME
NUT68 (BDIIxSPRD)xBDII NME
NUT89 (BDIIxSPRD)xBDII NME
NUT91 (BDIIxSPRD)xBDII NME
REF Rat Embryo Fibroblast
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contribution from the non-susceptible strains [6,7].
In another study of the same tumor material developed
in the inter-strain crosses expression profiling of tumor
and pre malignant cell lines was performed. A number of
genes were significantly differentially expressed between
EAC and pre/non malignant cell lines, and several of these
belonged to cancer-associated pathways [8]. One of the
genomic regions associated to development of EAC
identified in the association studies included Phf5a, and
gene expression profiling analysis revealed this gene was
down regulated in EAC derived cell lines.
The PHD finger-like domain protein 5a (PHF5A) is
ubiquitously expressed and is located in the nucleus.
The gene Phf5a and its human counterpart PHF5A
(former name Ini) are located on rat chromosome 7
(RNO7q34) and human chromosome 22 (HSA2213q2),
respectively. The rat gene consists of four exons, while
the human gene have five exons. Both genes encode a
highly conserved protein of 110 amino acids that contains a
PHD finger domain. The PHD-finger domain is composed
by eight amino acids and has been found in two major
groups of proteins. One group consists of transcriptional
activators, repressors and cofactors, and the second
major group consists of proteins involved in chromatin
modulating complexes such as acetyltransferase or
complexes containing acetyltransferase [9].
The alignment between the coding sequence of human
PHF5a to mouse Phf5a and rat Phf5a revealed a sequence
identity of 91% and 94%, respectively and at the protein
level the amino acid sequences are 100% identical between
the three species [10].
PHF5A acts as a transcription factor or cofactor in the
expression of the gap junction alpha 1 (Gja1) gene, which
is normally up regulated in uterus. The PHF5A protein
binds to the proximal region of the Gja1 promoter and
promotes the up regulation of Gja1 by estrogen [9,11]. The
Gja1 gene encodes a Gap junction alpha 1 (former name
connexin43) protein that is one of 21 different isoforms
that belongs to the connexin family. Connexins are
membrane proteins that form channels between adjacent
cells and mediate cell-to-cell communication [12-15]. Gja1
is expressed in various tissues like the brain, heart, ovary,
uterus and smooth mussels including the myometrium.
In the uterus, gap junctions are required for coordin-
ation of the contractions at the end of the pregnancy.
In the myometrium Gja1 is under control of a steroid
hormone as being up regulated by estrogen and down
regulated by progesterone [11].
The expression of GJA1 is often down regulated in
mammary carcinoma cell lines indicating that in these
cases the role of GJA1 in carcinogenesis in maintaining
cell differentiation and preventing transformation into can-
cer cells can not be fulfilled [16,17]. In addition it was foundthat the expression of GJA1 decreases with increased grade
of endometrial adenocarcinoma [18].
The aim of this study was to investigate the expression
of Phf5a and its effect on Gja1 expression in tumor and
non-malignant cell lines derived from the BDII rat
model with different genetic backgrounds. In addition,
the expression pattern of these genes was compared to
the expression pattern of the corresponding genes in the
human tumor samples of FIGO grades I-III.
Results
The gene expression of Phf5a and Gja1 in the rat samples
was measured in four groups defined by their cross origin
(BDIIxBN)xBDII or (BDIIxSPRD)xBDII and cell type
(EAC or NME). Five EACs and 5 NMEs with the BN
background and 6 EACs and 6 NMEs with the SPRD
background were analysed (Table 1). Gene expression of
PHF5A and GJA1 in the human material was measured in
30 human EACs in FIGO grade I-III (10 tumors from
each grade), and 26 benign (12 secretory phase and 14
proliferative phase) were analyzed with the students t-test
for differences between groups (Table 2).
Table 2 Overview of the human tumor material used in
this study
Sample Tumor grade Tissue
Endometrium Normal
14 Proliferative phase Benign
12 Secretory phase Benign
10 Type I Malignant
10 Type II Malignant
10 Type III Malignant
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ANOVA were conducted for analyses of differences among
replicates in the rat as well as the human material. There
were no significant differences detected among the
replicates in either of the data sets. Thus, the average
Ct values of the replicates were used in the following
calculations of the relative quantitative gene expression.
Any undetected Ct values for either of the genes were
set to the Ct value of 40 cycles, which corresponds to
expression at very low levels.
Pearson´s correlation test on log 2-fold change was
performed to explore potential correlation between Phf5a/
PHF5A and Gja1/GJA1. No expression correlation between
the two genes could be seen, in the rat or human material.
In the rat tumor set, comparison of the gene expression
of Phf5a and Gja1 between the EAC and NME samples
showed a slight, but not significant, decrease in in expres-
sion of Phf5a in the EAC cell lines. The corresponding test
for Gja1 revealed no significant differences. In comparisons
between all samples of the BN cross origin and the SPRDTable 3 The P-values obtained from the independent
sample t-test for differences between groups
Rat Phf5a Gja1
EAC NME 0.056 0.915
BN SPRD 0.376 0.784
BN/EAC SPRD/EAC 0.038* 0.528
BN/NME SPRD/NME 0.333 0.935
BN/EAC BN/NME 0.006** 0.606
SPRD/EAC SPRD/NME 0.991 0.727
Human PHF5A GJA1
Type I-III 0.262 0.4461
Prol Secr 0.685 0.156
Type I-III Prol/Secr 0.000*** 0.282
Type I Prol/Secr 0.002** 0.559
Type II Prol/Secr 0.000*** 0.517
Type III Prol/Secr 0.004*cp 0.081
* P< 0.05.
** P< 0.01.
***P< 0.001.cross origin, no significant differences were detected for
any of the genes investigated (Table 3).
When we performed the analysis separating groups by
tissue type, EAC and NME, and cross background,
(BDIIxSPRD)xBDII and (BDIIxBN)xBDII, still no signifi-
cant differences were detected for Gja1 in any of the
comparisons. For Phf5a significant differences were found
in comparisons between EACs developed in the BN and
those in the SPRD background with a lower expression in
the tumor cell lines derived from the progenies of the
(BDIIxBN)xBDII crosses (P<0.05). The EAC cell lines
developed in the (BDIIxBN)xBDII progeny displayed a
significant decrease in Phf5a expression (P<0.01) when
compared to the NMEs with the same background
(Figure 1A and Table 3).
In the human material no significant differences (P>0,05)
between the proliferative and the secretory phase of the
benign tumors for either PHF5A or GJA1 were seen,
and accordingly the two benign classes were merged
(Table 3). An ANOVA test on the tumor classes revealed
no significant differences among the different tumor
grades (P>0,05, but still we analyzed the classes separately.
For the gene GJA1 no significant difference in any of the
comparisons between malignant and benign material were
detected (Table 2, Figure 2B). For PHF5A all tumor classes
were up regulated compared to the benign samples,
where type II tumors differed most from the benign
samples (Table 3, Figure 2A).
Discussion
From the results of the association studies in the BDII
model of EAC, one small genomic region associated to
the development of EAC that included the Phf5a gene
was identified [6,7]. In an expression profiling study, the
Phf5a gene was shown to be down regulated in certain
EAC cell lines from tumors developed in the F2 and N1
progenies [8]. The chromosomal localization of Phf5a is
RNO7, band q34, and the PHF5A corresponding human
region is located on HSA22 (HSA2213q2), and the gene
is highly conserved through evolution.
It has been suggested that the PHF5A protein plays a
complex role as a general transcriptional activator for
different genes. Trappe et al. (2002) suggested the PHF5A
yeast orthologue plays a crucial roll for cell viability and
survival [9]. In C. elegans the Phf5a orthologue displays a
tissue- and stage-specific pattern of expression during
morphogenetic development [19]. In rat myometrium
the phf5a protein has been suggested to function as a
transcription factor for the gene Gja1 in the presence of
estrogen by binding to the proximal promoter region
and enhance expression of Gja1 [11]. The protein encoded
from the gene Gja1 is a component of the gap junctions
that form intercellular channels for diffusion of molecules
between cells. It has been suggested that GJA1 is down
Figure 1 Gene expression of Phf5a (A) and Gja1 (B) in NME and NUT rat cell lines. Gene expression of (A) Phf5a and (B) Gja1 in rat
endometrial adenocarcinoma and pre-malignant endometrial cell lines. The bars represent the mean delta delta Ct value in each group. The
median in each group is represented by horizontal line.
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through promoter hyper-methylation, and that it displays
tumor suppressor activity [17,20]. However, down regula-
tion of GJA1 through its promoter hyper-methylation was
shown not to be true for in human colorectal cancer
[20,21], and therefore silencing of the GJA1 was suggested
be mediated by other mechanisms through estrogen
activation. One possible mechanism could be up regulation
of Gja1 by Phf5a through the action of estrogen as sug-
gested by Oltra et al. [11].
In this study, we investigated the expression, and a
potential correlation of Phf5a and Gja1 in rat cell lines.
As the cell lines were derived from tumors developed inFigure 2 Gene expression of PHF5A (A) and GJA1 (B) in samples of FIG
expression in human endometrial adenocarcinomas of benign samples and
delta Ct value in each group. A horizontal line represents the median in eacrosses between the females of the BDII inbred strain,
susceptible to develop EAC and two non-susceptible
strains (BN and SPRD), the impact of the genetic back-
ground could also be taken into consideration. In human
the influence of the genetic background on the devel-
opment and path of tumourigenesis is difficult to grasp
in human clinical materials. Still, there are some cases
were specific alleles have a protective or enhancing effect
on the expression of mutation alleles in BRCA1/BRCA2
[22,23]. In inbred animal models there are good opportun-
ities to design crosses and experiments to enable studies of
the impact of the genetic background on the outcome
of carcinogenesis. The BDII rat model has been usedO grade I-III and benign samples. (A) PHF5A and (B) GJA1 gene
FIGO grade I-III tumor samples. The bars represent the mean delta
ch group.
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as well as the genomic level. In association studies, it
was proved that depending on cross background,
(BDIIxSPRD)xBDII and (BDIIxBN)xBDII, different genomic
regions were associated to the onset of tumors [7,24]. SKY
analysis of genomic aberrations in the cell lines derived
from the tumors developed among females in the cross
progenies, revealed that some aberrations in the genome
were common to both cross backgrounds and others
occurred only in one of the cross backgrounds [25].
Without considering the genetic background of rat
female progenies that developed tumors, the expression
of Phf5a in EAC cell lines was shown to be slightly lower
than the NME samples, but not significantly lower. By
separating the cell lines according to cross background,
a significant lower expression of Phf5a in the EAC derived
cell lines with the BN background compared to the
EACs from the SPRD background was revealed. Phf5a
was not differentially expressed in comparison with the
non-malignant cell lines in the SPRD background, but
in the BN background (Figure 1A). Accordingly, cross
set-ups such as in the BDII rat model, permit findings
that otherwise is difficult to uncover.
The normal function of GJA1/Gja1 is in the myometrium
is coordination of the contractions at the end of the
pregnancy, and is under control of a steroid hormone
Expression of GJA1 has been shown to be down regulated
in mammary tumors, lung cancer and endometrial
adenocarcinoma [18,26-29], as GJA1/Gja1 normally main-
tains cell differentiation and prevents transformation
into cancer cells [11,16,17]. In addition it has been found
that the expression of GJA1 decreases with increased
grade of endometrial adenocarcinoma [18].
This earlier results could not be validated in this study
as the Gja1 gene was not down regulated in the rat EAC
cell lines, and no significant differences between the
different cross backgrounds or between EACs and NMEs
were detected. It is known that the PHF5A protein binds
to the proximal region of the Gja1 promoter and promotes
the up regulation of Gja1 by estrogens as described in
transfections experiments [9,11]. In these experiments,
it was stated that PHF5A was localized in the nucleus,
where it binds to the GJA1 promoter and up regulates
the expression of GJA1 in the presence of estrogens in
a tissue specific and dose dependent way. In contrast to the
studies describes above [11], it could not be corroborated
that Phf5a regulate the expression of Gja1 in experimental
EACs as no correlation between the expression of Gja1 and
Phf5a could be seen (Table 3, Figure 1B).
The result of the expression study of Phf5a in rat
could not be verified in the human samples. Although
PHF5A was also down regulated in the human tumor
samples, but unexpectedly, it was more down regulated
in the human benign samples.Conclusions
To conclude, changes in expression in tumors for one of
the genes, PHF5A/Phf5a were found both in human
and rat, even if the pattern of changes is not com-
pletely consistent between the two species. The reason
for this discrepancy has to be further investigated. We
could not confirm suggestions made in earlier studies,
where it was shown that PHF5A regulate the expression of
GJA1. The impact of estrogen in this regulation has been
investigated in the same study [11]. We plan to investigate
and validate this in the material used in an extended study,
where we will also investigate the function of PHF5A as a
promoter for other genes.
The utmost important finding in this study was that,
by using an experimental model, we could successfully
show that certain aberrations in the tumors that lead to
changes in gene expression, and subsequent changes in
protein expression is dependent on the genetic back-
ground. Thus, the importance of using animal models as
a complement to clinical studies is obvious.
Material and methods
Rat tumor material
In order to study genetic aspects of EAC development,
intercross (F1, F2) and backcross (N1) populations were set
up by breeding BDII females to males from two different
strains with low EAC incidence (BN and SPRDCu3).
Females were examined weekly, suspected tumors were
were surgically removed and pathologically examined, and
cell cultures were established when possible [24]. The tu-
mors were pathologically classified as EAC, or other uterine
tumors. In some cases no cancer cells were detected when
pathologically examined. These tissues were referred to
non-malignant endometrium (NME) (Table 1) [8,30]. In
this study cell lines from tumors and pre/nonmalignant
tissues in the backcross female progeny were used (NUT).
In vitro cell culture conditions
Primary cell cultures from endometrial material (EAC
and NME) and rat embryo fibroblast (REF) cell line
were cultured in Dulbecco’s modified Eagle medium
(DMEM, Invitrogen) supplemented with 100 IU/100 μg/ml
penicillin/streptomycin, L-glutamine, MEM amino acids,
MEM Non-Essential Amino acids, MEM Vitamins solution
and 10% heat-inactivated fetal bovine serum, for 3–5
passages in order to obtain the required amount of cells.
The cells were grown at 37°C with a 5% CO2 and humidity
at 95% and harvested by trypzination at a confluence of
80-90%. In this study, a total of 22 primary cell cultures
(11 EAC and 11 NME) were used (Table 1).
Human tumor material
A total of 30 EACs in FIGO grade I-III (10 tumors from
each grade) embedded in archival formalin fixed paraffin
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FFPE endometrial tissues (12 of secretory phase and 14
of proliferative phase) were used. As the reference sample,
one sample from normal endometrium was used in the
normalization process (Table 2) [31] for further details).
Exctraction av RNA and RT-PCR
Total RNA was isolated from the EAC/NME cell lines
(Table 1) using the Qiagen® AllPrep RNA Mini Kit according
to the manufacturer’s protocol. Total RNA was extracted
from human endometrial paraffin imbedded tissue
samples (Table 2) using Qiagen® AllPrep RNA FFPE
Kit. RT-PCR was performed on 500 ng of total RNA,
using the High Capacity RNA-to-cDNA Kit according to
the manufacturer’s protocol (Applied Bio-systems, USA).
Quantitative PCR (qPCR) of Phf5a and Gja1 in rat tumors
A total of 11 EAC and 11 NME cell lines were included
in the qPCR analysis. The house keeping gene, Gapdh
was used as an endogenous control and the Rat embryo
fibroblast cell line (REF) was used as an exogenous
control. Template cDNA was added to TaqMan Universal
Master Mix (Applied Biosystems, USA) in a 25 μl reaction
with specific pre-designed probes for Phf5,a Gja1 and
Gapdh (Applied Biosystems). Reactions were performed
in triplicates and the averages threshold cycle number
was used for further analysis. Relative gene expression
quantification was calculated according to the comparative
Ct method using Gapdh as an endogenous control and
REF as calibrator. Final results were determined as follows:
2–(ΔCt sample–ΔCt calibrator), where ΔCt values of the calibrator
and sample were determined by subtracting the Ct value of
the target gene from the value of the Gapdh gene.
Quantitative PCR (qPCR) of PHF5A and GJA1 in human
tumors
Total RNA from paraffin imbedded tissue samples was
used for qPCR. The house keeping gene, GAPDH was
used as an endogenous control and RNA from the
endometrial tissue was used as an exogenous control.
The qPCR reaction setup followed the same procedure
as for the rat samples.
Statistical analysis
For statistical evaluations of gene expression data, Ct
values for differences among replicates was analyzed by
ANOVA. For comparisons of expression differences
between normal and malignant tissues, independent
sample t-test was applied on the log 2-fold change
(PASW Statistics 20, SPSS Inc, Chicago, USA). In both
tests the null hypotheses were assuming no differences
between replicates, and no differences between tissue
types, respectively. The Pearson correlation test was
performed to check for expression correlation betweenPhf5a/PHF5A and Gja1/ GJA1. The significance levels
were set to P<0.05 in all statistical tests. Furthermore,
the tumor material from the rat samples was analyzed
for differences in gene expression between the two
backgrounds (BN and SPRD).
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